Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial

The Lancet Oncology 2026

View at publisher
Authors: Rianne L Seefat, Sonja B. Vliek, Vincent M. T. de Jong, Sara Balduzzi, Ingrid A.M. Mandjes, Valesca P. Retèl, I. Eekhout, Marjolein Delfos, Margaret Schot, M. Holtkamp, Mandy M van Rosmalen, Brenda Leeneman
+33 more Hedwig Blommestein, Alwin D R Huitema, Efraim H. Rosenberg, Petra M. Nederlof, Terry W S Chan, Anna van Rhenen, Mariëlle J. Wondergem, Nicolaas P M Schaap, Tjeerd J.F. Snijders, Marjolein van der Poel, Wouter J. Plattel, Erik van Werkhoven, Harm van Tinteren, Marjolein L. Smidt, Jelle Wesseling, Jos Jonkers, Sven Rottenberg, Marie-Jeanne T F D Vrancken Peeters, Carlijn Voermans, John H. Maduro, Judith R. Kroep, Carolien P. Schröder, Evelien J M Kuip, Anthony Gonçalves, Janine Nuver, A N Machteld Wymenga, Rhodé M. Bijlsma, Elsken van der Wall, Inge R. H. M. Konings, Vivianne C G Tjan-Heijnen, Mojca Jongen‐Lavrencic, Agnes Jager, Sabine C Linn
DOI: 10.1016/s1470-2045(26)00131-2
Cited by: 1
References: 28

Fields of Study & Subjects

PARP inhibition in cancer therapy DNA Repair Mechanisms Breast Cancer Treatment Studies

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
7
Pages
795–807
Publication date
29 June 2026
Language
EN